Physician profile
Eric J Binder
NPI 1437149341
$15,045.27
in general payments reported to CMS, 2019-2025
49 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,483 · 2020: $1,713 · 2021: $3,528 · 2022: $3,623 · 2023: $3,264 · 2024: $1,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,697.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,695.83 | 2019-2024 | Qulipta, Vraylar, Linzess |
| Novo Nordisk INC | $1,674.57 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,478.07 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,238.27 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $994.49 | 2019-2024 | Prolia, Evenity, Repatha |
| Pfizer INC. | $951.81 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $803.54 | 2019-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $786.99 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $424.63 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Amarin Pharma, INC. | $408.35 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $341.49 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $313.53 | 2019-2024 | Eliquis |
| Merck Sharp & Dohme LLC | $304.27 | 2019-2024 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Kowa Pharmaceuticals America, INC. | $268.55 | 2019-2022 | |
| Abbott Laboratories | $247.14 | 2021-2024 | Freestyle Libre, Freestyle Libre 3 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Binder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.